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Abstract
Osteoarthritis is a significant public health problem and is rapidly increasing in 
prevalence with the aging population. Pain is the most disabling consequence of 
osteoarthritis. Treatment for pain is inadequate and needs to be addressed with new 
therapeutic modalities. Chronic pain is often the result of peripheral and central 
pain sensitization which reduces the pain threshold and increases the perceived 
pain response to noxious and even non-noxious stimuli. Neurotoxins can reduce 
this sensitization by various mechanisms and are a fertile area of research for the 
treatment of chronic pain. Botulinum toxins, vanilloids, and conotoxin have all 
been studied for the treatment of chronic pain. Botulinum toxins and vanilloids 
have the greatest potential as analgesics for chronic joint pain thus far. Monoclonal 
antibodies directed against nerve growth factor have also been developed for the 
treatment of chronic joint pain due to osteoarthritis. These antibodies are not 
technically neurotoxins but have significant analgesic potential. However, they may 
have undesirable side effects and are still being evaluated as possible therapies for 
chronic osteoarthritis pain.
Keywords: osteoarthritis, chronic pain, arthritis, neurotoxins, anti-nerve 
growth factor
1. Introduction
Chronic joint pain is a world-wide problem. Osteoarthritis (OA) is the most 
common cause of chronic joint pain and is increasing in prevalence. In the United 
States alone, osteoarthritis affects approximately 27 million adults and is expected 
to exceed 67 million by the year 2030 [1, 2]. Although disability due to osteoarthritis 
varies, pain is the most disabling symptom affecting OA patients [3, 4]. To date, there 
are no disease modifying treatments for osteoarthritis. Treatment goals are focused 
on relief of symptoms and minimizing disability. The direct costs of treatment of 
OA combined with the indirect costs due to lost wages are substantial. According to 
one estimate, this cost accounts for 2% of the annual gross domestic product [5, 6]. 
Management of chronic pain from OA is challenging. Non-pharmacologic options 
include education, exercise, weight reduction, acupuncture, and joint protection, but 
these practices are generally insufficient to provide joint pain relief. Pharmacologic 
options  include systemic and intraarticular therapies [7]. Insufficient pain relief, 
intolerable drug side effects and drug interactions increase the risk-benefit ratio for 
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available pharmaceutical therapies [8]. Even surgical therapies for degenerative joint 
disease may not be effective. Knee joint lavage has been shown to be no more effec-
tive for alleviation of pain than placebo [9, 10].
In particular, end stage disease provides challenges for effective therapy. 
Opioids can sometimes be effective when other therapies have lost efficacy, but the 
use of narcotics for chronic pain is undesirable due to eventual dependence and loss 
of efficacy, the need for dose escalation to maintain effectiveness, and the rising 
problem of opioid abuse and overdose that has occurred since the use of long-
acting narcotics have been available [11]. In addition, unacceptable side effects, 
particularly in the elderly who are more likely to have end stage osteoarthritis 
pain, makes the use of opioids a poor choice [12]. Finally, opioids may not have 
any increased efficacy for chronic OA pain compared with non-narcotic therapies 
[13]. The efficacy of intra-articular treatments such as corticosteroids and hyal-
uronic acid preparations have not been clearly demonstrated. For this reason the 
American Academy of Orthopedic Surgeons recommends against viscosupplemen-
tation and felt the evidence to be inclusive regarding corticosteroid injections for 
osteoarthritis [14].
Surgical treatment for end stage osteoarthritis is limited. Total joint replacement 
is generally considered to be effective for short and long-term pain relief and usu-
ally achieves positive clinical and functional outcomes [15, 16]. However, surgical 
treatments are not without risk of complications. These include systemic complica-
tions such as pulmonary embolism, but also local complications such as dislocation 
of hips, wound and joint infection, periprosthetic fracture, aseptic loosening, patel-
lar maltracking, rupture of the extensor mechanism, stiffness with reduced range 
of motion, heterotopic ossification, metal hypersensitivity, vascular injury or bleed-
ing, or nerve palsy. Success rates vary but as many as 1 in 5 patients undergoing total 
knee arthroplasty (TKA) are not satisfied with the outcome [16]. Obese patients 
are at increased risk for complications following TKA. Pre-operative management 
including weight loss, optimization of diabetes treatment, venous thromboembo-
lism prevention, and physical therapy can help to minimize these complications 
[17]. Even so, some individuals will not be surgical candidates. Clearly other options 
are needed for effective pain relief to minimize disability and optimize function in 
patients who are not candidates for surgery and for whom standard analgesics have 
not been helpful.
Palliative therapy is specialized medical care focused on providing relief from 
the symptoms and stress of a serious illness. The goal is to improve quality of life and 
enhance physical function, but without treating or attempting to cure the underly-
ing disease. Palliative therapy for end stage osteoarthritis is a concept that has been 
explored but due to a lack of effective therapies has not been very successful [18].
2. Neurobiology of chronic pain
Pain is the result of nerves transmitting a noxious signal, usually the result of 
some sort of injury, to the brain where it is perceived as pain. This is an important 
signal for the organism experiencing the injury to withdraw or avoid the stimulus 
that is producing the pain. Chronic pain results when nociceptive systems are 
altered so that there is no longer a direct relationship between a noxious stimulus 
and pain perception. These alterations are due to plasticity of the nervous system 
whereby peripheral nerves become sensitized, or spinal cord neurons become 
increasingly excitable. Projections from the spinal cord to higher centers can result 
in changes to descending inhibitory controls that are initiated in the midbrain and 
brainstem. All these changes together tend to alter the perceived response to any 
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stimulus and thus lead to persistent pain states. This plasticity appears to be revers-
ible and thus amenable to pharmacologic therapies [19].
Peripheral sensitization is thought to be the result of inflammation or nerve 
injury which alters nociceptive receptors causing increased intracellular calcium 
and activated intracellular protein kinase C and tyrosine kinases. These mediators 
phosphorylate sensory neuron-specific sodium channels and Transient Receptor 
Potential Vanilloid 1 (TRPV1) receptors causing a reduction in the depolarization 
threshold and reduced pain threshold. Nociceptive neurons themselves release 
chemical stimulants such as substance P (SP) and calcitonin gene-related peptide 
(CGRP) which amplify the local inflammatory response by interacting with local 
inflammatory cells and nearby blood vessels. This “neurogenic inflammation” 
causes vasodilation and edema, and increases local inflammation adding to periph-
eral sensitization [20]. Pharmacologic inhibition of this sensitization process is an 
attractive target for analgesia, as reducing sensitization would be expected to reduce 
the pain perception without eliminating the important pain defense mechanisms. 
Given the critical involvement of neuropeptides in the development of sensitiza-
tion, the efficacy of neurotoxins was hypothesized for treatment of chronic pain.
3. Botulinum toxins as analgesics
3.1 Botulinum toxin background and human studies
There are eight serotypes of botulinum toxin. All are products of the bacterial 
genus Clostridium. Types A-G have been fully characterized and have varying dura-
tions of action, and enzymatic targets. They all cleave components of the soluble 
N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor 
(SNARE) proteins. The inability of the disrupted SNARE proteins to bring the syn-
aptic vesicle membrane and the terminal plasma membrane of the peripheral nerve 
in close proximity results in an inability of the two membranes to fuse and failure 
of the nerve to release neurotransmitter such as acetylcholine (ACh). This produces 
the dramatic paralytic activity of botulinum toxin [21]. The eighth serotype, H, 
has been recently described, but its gene sequence has been withheld due to public 
safety concerns since it is considered the deadliest substance in the world [22].
Botulinum toxins A and B have been used for some time to treat painful muscle 
dystonias such as torticollis. It was thought that the paralytic effect of the toxin on 
motor units in the dystonic muscle was responsible for the pain relief that accompa-
nied this treatment. But it was observed that pain relief preceded the muscle weak-
ness that was expected with these treatments. This observation led to early studies 
of the use of intra-articular onabotulinum toxin (Type A) for end stage osteoarthri-
tis [23]. Subsequent similar studies have been done and summarized in meta-anal-
yses and systematic reviews. Their findings suggest that even for end stage arthritis 
pain, intra-articular botulinum toxin has modest beneficial effects in patients with 
refractory joint pain [24–27]. Studies of shoulders and knees predominated but one 
study treated refractory ankle osteoarthritis pain and one treated refractory pain 
after total knee arthroplasty. Doses used were between 100 and 200 IU onabotuli-
num toxin A (BOTOX), 200–500 IU abobotulinum toxin A (Dysport) and 2500 IU 
rimabotulinum toxin B (Myobloc). Controls in these studies were variable ranging 
from triamcinolone to saline to unspecified placebo. Some studies used botulinum 
toxin diluted with lidocaine and compared to saline with lidocaine. One small study 
of 75 patients compared intra-articular (IA) botulinum toxin A to injection with 
2 ml sodium hyaluronate in patients with symptomatic ankle OA and found no 
difference in effectiveness between the two interventions [28]. Since the American 
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Academy of Orthopedic Surgeons has stated in their evidence based guidelines 
for the treatment of OA of the knee that viscosupplementation cannot be recom-
mended, this comparison may be less than appropriate [29].
Studies of IA botulinum toxin use in humans have not reported significant safety 
issues. Although weakness was initially a concern, it was not found in extensive 
safety evaluations [23, 26]. Since a single injection provides pain relief for up to 
6 months, fewer injections may be required as compared to corticosteroid or visco-
supplementation injections and therefore, the risk of infection is minimized.
3.2 Botulinum toxin studies in preclinical models of joint pain
In an effort to better understand the mechanism of action of pain relief seen 
with botulinum toxin and to precisely define functional outcomes, a variety 
of animal studies have been done (Table 1). Botulinum toxins have been given 
intraarticularly for joint pain in mice, rats and dogs. IA botulinum toxin appears 
to be effective for chronic arthritis pain but not acute joint pain in mice, support-
ing the idea that botulinum toxin reduces peripheral sensitization by inhibiting 
neuropeptide release in the periphery [30, 31]. Only one study evaluated efficacy of 
rimabotulinum toxin for osteoarthritis pain in mice and found that it reduced both 
spontaneous and evoked pain behaviors [32]. In dogs with chronic lameness due to 
stifle, hip or elbow osteoarthritis IA onabotulinum toxin produced improvement in 
several force platform variables including vertical impulse, peak vertical force and 
in the Helsinki chronic pain index compared to the placebo group after 12 weeks. 
The secondary outcomes of subjective pain score and the need for rescue analgesics 
were not significantly improved in the botulinum toxin treated group compared 
to placebo. No major adverse events were detected [33]. A second study in dogs 
designed to detect adverse effects of IA botulinum toxin compared toxin injection 
to placebo in healthy beagle dogs. This study evaluated dynamic and static weight 
bearing, range of motion, joint tenderness, synovial fluid, neurologic function and 
electrophysiologic recordings, and histopathology of joint structures and adjacent 
muscles and nerves. Intra-articular botulinum toxin A did not produce significant 
clinical, cytological, or histopathological adverse effects in healthy dogs, but based 
on the electrophysiological recordings that found low compound muscle action 
potentials in 2 dogs in the botulinum toxin injected limb, the authors concluded 
that toxin may spread from the joint, but that its clinical impact is probably low 
[34]. In rats with inflammatory arthritis of the temporal mandibular joint (TMJ) 
produced by immunization with bovine serum albumin (BSA) and subsequent 
intra-articular challenge with BSA, injecting the joint with botulinum toxin A sig-
nificantly reduced nociceptive behaviors that resulted from IA injection of low dose 
formalin into these inflamed joints. These authors demonstrated that the trigeminal 
ganglion of botulinum A treated arthritic animals released less substance P (SP) 
and calcitonin gene related peptide (CGRP) than saline treated arthritic animals 
but glutamate release was not affected. Glutamate receptors AMPA and NMDA 
were also unchanged in botulinum treated ganglia compared to saline treated 
controls. Periarticular tissues from the arthritic TMJs released increased amounts 
of interleukin 1-β (IL-1β) and tumor necrosis factor α (TNFα). Treatment with 
botulinum toxin reduced IL-1β release but had no effect on TNFα [35]. In another 
study of rats with adjuvant-induced arthritis induced in the tibial-tarsal joint, 
mechanical and thermal hyperalgesia and TRPV1 expression in the L4-5 dorsal root 
ganglia (DRG) were measured. DRGs were also stained for the presence of cleaved 
synaptosomal-associated protein of 25 kDa (SNAP-25)—the cleavage product of 
botulinum toxin A—and for transient receptor potential vanilloid 1 and put TRPV1 
in parentheses TRPV1 and CGRP. TRPV1 expression increased significantly in 
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the arthritic animals’ DRGs and arthritic animals demonstrated mechanical and 
thermal hyperalgesia. Botulinum toxin A increased the paw withdrawal threshold 
and latency to both mechanical and thermal stimuli and reduced TRPV1 expression 
in a dose-dependent manner. TRPV1 transcription was likewise increased with 
Complete Freund’s Adjuvant (CFA) induced arthritis but botulinum toxin A did not 
alter this increased transcription. Using immunofluorescent staining, these authors 
found that the increase in TRPV1 and CGRP co-expressing neurons which was the 
result of CFA arthritis was reduced by botulinum toxin in a dose dependent manner. 
Since botulinum toxin exerts its effects by cleaving SNAP-25 and thus preventing 
Arthritis model Experiment Results Reference
Murine CFA, COL IA BoNT/A vs. sham Reduced spontaneous and evoked pain 
behaviors in CFA arthritis, reduced 
spontaneous pain behavior in COL 
arthritis
[30, 31]
Murine COL IA BoNT/B vs. saline 
or sham injection
Improved visual gait analysis, improved 
joint tenderness
[32]
Dog, OA, multiple 
joints
IA BoNT/A vs. 
placebo
Outcome measured 
after 12 weeks
Improved peak vertical force, improved 
Helsinki chronic pain index
[33]
Healthy beagles 
(safety study)
IA BoNT vs. placebo No adverse clinical, cytological, or 
histopathological effects. Some EMG 
evidence for spread outside the joints 
to muscle
[34]
Rat BSA TMJ 
inflammatory 
arthritis
IA BoNT/A followed 
by pain induction 
with formalin 
injection
Significantly reduced pain behaviors, 
reduced SP and CGRP release, no 
change in glutamate release, reduced 
release of IL-1β but not TNFα
[35]
Rat CFA tibiotarsal 
joint
IA BoNT/A (dose 
ranging) compared 
to CFA alone and 
saline control
All pain outcomes improved in a dose 
dependent fashion. (Mechanical 
and thermal hyperalgesia) TRPV1 
expression reduced but not 
transcription, thought due to the 
observed reduced movement of TRPV1 
to the cell membrane
[36]
Rat CFA ankle 
arthritis
Plantar injection 
of capsaicin and 
formalin and 
plantar incision 
as standardized 
pain models. Also 
included SNI model
BiTox—unique 
nonparalyzing 
botulinum toxin 
molecule
CFA induced swelling reduced, 
mechanical hyperalgesia but not 
thermal hyperalgesia reduced. No 
effect on acute pain from capsaicin 
or formalin but reduced secondary 
mechanical hyperalgesia after plantar 
capsaicin injection. Plantar incision pain 
response reduced after day 2. Reduced 
neuropathic pain in the SNI model
[37]
ACIA model in mice Genetic modification 
of mice to express 
the conotoxin 
ω-conopeptide 
MVIIA vs. wild type
Pain was suppressed but joint 
inflammation was increased and more 
destructive in genetically modified mice
[55]
CFA—complete freund’s adjuvant induced arthritis, COL—collagenase-induced osteoarthritis, BoNT/A—
onabotulinum toxin type A, BoNT/B—rimabotulinum toxin type B, BSA—bovine serum albumin, TMJ—temporal 
mandibular joint, SNI—spared nerve injury, ACIA—antigen and collagen-induced arthritis.
Table 1. 
Preclinical studies of botulinum and other toxins as analgesics for arthritis pain.
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release of neuropeptide by preventing fusion of vesicles with the terminal mem-
brane, the presence of cleaved SNAP 25 localized with TRPV1 in the DRG was 
analyzed. Co-localization of cleaved SNAP-25 with TRPV1 in the botulinum toxin A 
group was clearly seen 5 days after botulinum toxin injection. This was not seen in 
the sham and CFA saline control groups. These authors speculated that botulinum 
toxin A may prevent TRPV1 expression on DRG neurons by inhibition of TRPV1 
trafficking to the cell membrane after retrograde transport of botulinum toxin 
from the periphery to the DRG since the expression of the TRPV1 receptor has been 
shown to be dependent on exocytosis that requires interactions with proteins of the 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
complex consisting of SNAP-25 [36]. The presence of botulinum toxin in the DRG 
would prevent the SNARE complex from functioning normally to move TRPV1 to 
the cell membrane. A botulinum toxin A based molecule—BiTox—has been synthe-
sized that is reported to retain neuronal silencing capacity without causing paraly-
sis. This molecule reduces plasma extravasation and inflammatory edema but is not 
transported to the DRG ganglia or dorsal horn and does not inhibit pain behaviors 
in response to formalin or capsaicin and does not inhibit formalin-induced c-Fos 
expression in the dorsal horn. It was found to strongly reduce A-nociceptor medi-
ated secondary mechanical hyperalgesia due to CFA joint inflammation or capsaicin 
injection and decreased hypersensitivity from nerve injury. The authors concluded 
that this botulinum toxin based molecule could reduce local release of neuromodu-
lators from C fibers without impairing C nociceptive signaling function [37].
4. Vanilloids as analgesics
4.1 Vanilloids and their receptors background
Vanilloids such as capsaicin (the active ingredient in hot chili peppers) and 
resiniferatoxin (a product of the plant Euphorbia resinifera) were first notable for 
their ability to produce burning pain when administered topically. Later, both 
molecules were found to have analgesic potential and subsequent work identified 
the non-selective cation channel to which these compounds bind. This receptor was 
found to be located on the dorsal root and trigeminal ganglia of various species. 
Subsequent work identified the channel, allowed cloning and cDNA characteriza-
tion, and revealed that the channel could be activated not only by vanilloids but also 
by heat suggesting a role in thermosensation. The receptor was named transient 
receptor potential vanilloid 1 (TRPV1) and other ligands were identified making it a 
transducer of many types of noxious stimuli [38].
Because of the variety of ligands, TRPV1 was considered a likely target for 
analgesia. Agonists such as vanilloids were noted to cause desensitization of these 
channels and in rodents as well as humans, pain behaviors could be alleviated 
with vanilloid treatment. TRPV1 knockout mice demonstrated reduced thermal 
hypersensitivity with inflammation. TRPV1 antagonists were shown to reverse 
pain behavior in rodents with a wide variety of painful conditions including 
inflammation, osteoarthritis and cancer. Both agonists and antagonists have been 
considered as analgesic therapies. Although systemic administration of vanil-
loids demonstrated analgesic efficacy in preclinical pain models, because of the 
undesirable systemic side effects of these compounds, most therapeutic trials have 
focused on local or topical administration of these compounds. Undesirable effects 
include hypotension, respiratory compromise and other negative effects on reflex 
pathways. Less pungent analogs were found to be less efficacious with respect to 
analgesia [38].
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4.2 Vanilloids as analgesics—Human and pre-clinical studies
In humans, current treatment of joint pain with vanilloids is limited to topical 
therapies. Pain relieving creams such as Zostrix® and patches such as Salonpas Hot 
Capsicum Patch® are available over the counter and contain capsaicin as the active 
ingredient. Multiple clinical trials have found modest benefit for osteoarthritis from 
low dose topical capsaicin [39–41]. More recently, a high dose 8% capsaicin patch 
has been approved for the treatment of post-herpetic neuralgia. According to the 
package insert, application of the patch requires careful adherence to application 
instructions by the health care professional and local anesthesia for the patient prior 
to application and systemic analgesics as needed in the post-application period. 
Interestingly, results from clinical trials of this drug for treatment of painful HIV 
neuropathy did not show clinical benefit [42, 43].
Resiniferatoxin (RTX) is an ultra-potent capsaicin (CAP) analogue [44], that is 
several thousand-fold more potent than CAP [45]. RTX in low concentrations pro-
duces a slow and sustained depolarization of membrane potential, preventing the 
generation of action potentials but causing less toxicity. A single IA injection in rats 
has been found to reduce hyperalgesia due to carrageenan induced joint pain [46].
RTX has been studied in clinical trials for other painful conditions. When 
given intravesicularly for interstitial cystitis and painful bladder syndrome, 
it did not improved overall symptoms of pain, urgency, frequency or noc-
turia [47, 48]. Adlea™ (4975) is another CAP analogue under development 
for the treatment of post-operative musculoskeletal pain, osteoarthritis and 
tendinopathy. Phase II trials of intra-articular injection of this compound 
were encouraging but no further clinical trials appear to have been performed 
[38]. Zucapsaicin (Civamide) is the cis-isomer of capsaicin, and functions as 
a TRPV1 blocker. Phase III trials have been done with topical civamide for OA 
knee pain [49]. This topical therapy is not absorbed systemically, is well toler-
ated, and produced significant improvement in Western Ontario and McMaster 
Universities Arthritis Index (WOMAC) physical function score, pain score and 
subject global evaluation. Improvement was maintained for a year. This drug 
has not yet been approved by the US FDA.
4.3 TRPV1 antagonists as analgesics
Several TRPV1 antagonists have also been identified that act as analgesics [50]. 
Some are more selective than others, complete nonselectivity producing inhibition 
of all modes of TRPV1 activation (protons, heat and capsaicin). More selectivity 
Arthritis model Experiment Results Reference
Rat carrageenan-
induced acute joint 
pain
IA RTX vs. vehicle given 
24 hours after arthritis induction 
in a dose ranging study
Significant reduction in 
pain behavior with RTX 
treatment
[46]
Rat MIA model—
early phase
A-425619 given IP in a 
dose range during acute 
inflammatory phase
47% reduction in 
weightbearing asymmetry. 
Prolonged benefit
[50, 51]
Rat MIA model—late 
phase
A-889425 and A-995662 given 
orally
Reduced loss of grip 
force within 1 hour and 
maintained up to 8 hours
[50, 52, 53]
IA—intra-articular, RTX—resiniferatoxin, MIA—monosodium iodoacetate.
Table 2. 
Preclinical studies of vanilloid agonists and antagonists as analgesics for arthritis pain.
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appears to improve the side effect profile. Centrally active TRPV1 antagonists 
appear to provide greater analgesia when given systemically or intrathecally in 
preclinical models of OA pain. Most preclinical studies of OA have been done in the 
monosodium iodoacetate (MIA) model in the rat (Table 2). Rats with MIA-induced 
arthritis pain demonstrate reduced weightbearing of the affected limb, pain with 
movement of the joint and hypersensitivity of uninjured tissues (secondary allo-
dynia of the hind paw). These pain behaviors are thought to be due to both central 
and peripheral sensitization. TRPV1 antagonists appeared to be analgesic during 
both the acute inflammatory phase of MIA pain and later during the chronic phase 
[50–53]. Analgesia appears to improve with repeated dosing and side effects such 
as hyperthermia abate with some of the investigational TRPV1 antagonists. The 
potency of hyperthermia induction seems to relate most closely to the blockade of 
proton-induced TRPV1 activation [50].
Only a few TRPV1 antagonists have been used in clinical trials. ADZ1386 given 
orally in two different doses did not reduce OA pain more than placebo. A study in 
dogs with hip OA using oral ABT116 did not improve the total pain score, pain sever-
ity or pain interference score, but did reduce rescue medication use, increased night 
time activity levels and briefly produced an acute hyperthermic effect. NEO 6860, 
which is specific for blocking capsaicin activation of the target, with little or no effect 
against pH or heat activation, underwent a first-in-human phase I trial of the safety 
and efficacy of the drug in healthy human subjects [54]. The dose ranging study 
included 64 subjects and measured pharmacodynamics with a intradermal capsaicin 
test as well as pharmacokinetics. The drug was rapidly absorbed with a half-life of 
between 4 and 8 hours. Side effects included headache, paresthesia, nausea, and 
dizziness. Study participants were monitored specifically for increase in temperature 
and heat pain threshold/tolerance, but these were not noted. At all doses, most 
subjects reported a rapid onset, transient sensation of “feeling hot”. The authors con-
cluded that this compound had potential for development for treating OA-associated 
pain and future clinical studies were planned but have not yet been initiated.
5. Other potentially analgesic neurotoxins
5.1 Conotoxin
Ziconotide (ω-conopeptide MVIIA) is a synthetic compound of the neurotoxin 
ω-conopeptide derived from the Conus Magus fish hunting marine snail found in 
the Pacific Ocean. It selectively binds to the N-type voltage-gated calcium channels 
found in the laminae of the spinal cord’s dorsal horn and blocks these channels. This 
blockade prevents calcium influx and halts neurotransmission thereby preventing 
nociceptive signaling. Pain transmission messages are prevented from arriving at 
the brain. It is FDA approved for intrathecal use for severe chronic pain in individu-
als who are intolerant of or refractory to other treatments including intrathecal (IT) 
morphine, but has demonstrated some serious side effects such as suicidal ideation 
and psychosis [55].
In a study of transgenic mice bred to express a membrane-tethered form of the 
conotoxin ω-conopeptide MVIIA under control of a nociceptor-specific gene, who 
were subjected to unilateral induction of joint inflammation with the antigen- and 
collagen- induced arthritis (ACIA) model, pain was effectively suppressed, but joint 
inflammation became persistent and more destructive. The authors concluded that 
blockade of CaV2.2-mediated calcium influx and nociceptive signaling by this toxin 
impaired recovery from induced inflammatory arthritis. They concluded that this 
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blockade could lead to potentially deleterious and devastating effects if used during 
inflammation [55].
5.2 Tetrodotoxin
Another neurotoxin studied as a potential analgesic is tetrodotoxin (TTX). 
Voltage-gated sodium channels (VGSCs) are critical for neuronal function and dys-
functional VGSCs have been implicated in several pain states. There are nine isoforms 
of the sodium channel alpha-subunit (Nav1.1–1.9 in mammals). Only Nav1.1–1.4 and 
Nav1.6–1.7 subtypes (TTX-sensitive channels) can be blocked by nanomolar con-
centrations of tetrodotoxin. Micromolar concentrations are required to block Nav1.5 
and Nav1.8–1.9 subtypes (TTX-resistant channels) [56]. Although it appears to have 
little effect on acute pain further studies are needed. Analgesic efficacy in preclinical 
inflammatory pain models demonstrated promising effects of systemic administra-
tion for mechanical hyperalgesia and the neurogenic inflammatory response to injury. 
There are contradictory results for TTX efficacy for neuropathic pain. Effectiveness 
in preclinical models of neuropathic pain varied depending on dose, route of applica-
tion, and appeared more effective in acute neural injury than in chronic neuropathic 
pain. In one clinical trial of tetrodotoxin for chemotherapy-induced neuropathic 
pain, injected TTX did not have a significant effect on pain [57]. There have been no 
specific studies evaluating tetrodotoxin for the treatment of chronic joint pain.
6. Anti-nerve growth factor
Thought not technically neurotoxins, several monoclonal antibodies have been 
developed against nerve growth factor (NGF) specifically for the treatment of 
chronic pain, and specifically for pain from OA. Tanezumab was the first of these 
to be developed. Three other companies have now created similar antibodies. 
Tanezumab was in phase III studies when the US FDA placed a hold on further 
clinical trials after an increase in joint destruction was observed in patients who 
had been given this drug. After that, preclinical studies suggested that this class 
of drugs could damage the autonomic nervous system, which delayed further 
research [58]. Since the hold was released in 2015, phase III clinical trials are being 
repeated. Results from those that have been published show that these biologic 
therapies appear to be effective with acceptable side effect profiles [59–61]. These 
therapies are administered parenterally, and therefore are systemically active. These 
antibodies have significant potential to improve analgesia for chronic arthritis pain. 
Alternative routes of administration such as IA will be of interest.
7. Conclusions
Chronic joint pain is a significant public health problem that will only increase 
along with the aging population. In the absence of disease modifying treatments 
for OA, the need for better pain therapies will continue to increase. Neurotoxins 
can be helpful as adjunct treatments for pain, particularly in cases where peripheral 
sensitization has lowered pain thresholds and increased pain perception. Advances 
in understanding of the pathophysiologic mechanisms of nociception and sensitiza-
tion and elucidation of the specific functions of the various neurotoxins will allow 
more advanced development of toxins that may avoid potential side effects and 
more specifically reduce pain perception.
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